{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:38Z","timestamp":1791244658910,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted recombinant zoster vaccine (RZV) has been developed to prevent herpes zoster (HZ), but there are no recommendations for use in this population. In this single-center prospective observational cohort study, we assessed the safety and reactogenicity of RZV, as well as incidence of graft-versus-host disease (GVHD) and confirmed cases of HZ after vaccination. Between December of 2018 and June of 2020, patients aged \u226518 years received 2 doses of RZV between 9 and 24 months after HCT, with the doses separated by \u22658 weeks. One hundred and fifty-eight patients (mean age, 55 years; 42% women) received \u22651 dose (total vaccinated cohort), and 150 patients (95%) received 2 doses (modified total vaccinated cohort). Solicited reactions occurred in 92.1% of patients (grade 3, 32.5%), owing mostly to injection site pain, which occurred in 86% (grade 3, 16%). The cumulative incidence of GVHD in the peri-vaccination period was no different than in historical controls (adjusted incidence rate ratio, 1.05; 95% confidence interval, 0.8-1.38). There were 4 cases of HZ in the total vaccinated cohort (2.5%) and 3 cases in the modified total vaccinated cohort (28.3\/1000 person-years). Among recipients of allogeneic HCT, RZV was safe, tolerable, and did not increase rates of GVHD. Future clinical trials are needed to determine the immunogenicity and efficacy of RZV in this population.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003749","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T11:35:33Z","timestamp":1615548933000},"page":"1585-1593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-2005","authenticated-orcid":false,"given":"Emily","family":"Baumrin","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Izaguirre","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4519-6898","authenticated-orcid":false,"given":"Bruce","family":"Bausk","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-4403","authenticated-orcid":false,"given":"Monica M.","family":"Feeley","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camden P.","family":"Bay","sequence":"additional","affiliation":[{"name":"Center for Clinical Investigation, Brigham and Women\u2019s Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-0518","authenticated-orcid":false,"given":"Nicolas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"1","key":"2021031815154413700_B1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1083-8791(00)70051-6","article-title":"Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome","volume":"6","author":"Koc","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021031815154413700_B2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.bbmt.2010.10.025","article-title":"High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation","volume":"17","author":"Su","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2021031815154413700_B3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","article-title":"Infection with varicella-zoster virus after marrow transplantation","volume":"152","author":"Locksley","year":"1985","journal-title":"J Infect Dis"},{"key":"2021031815154413700_B4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/9781118416426.ch89","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation","author":"Ho","year":"2016","edition":"5th ed."},{"issue":"5","key":"2021031815154413700_B5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2013a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2021031815154413700_B6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjc.1989.88","article-title":"The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation","volume":"59","author":"Selby","year":"1989","journal-title":"Br J Cancer"},{"issue":"8","key":"2021031815154413700_B7","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2007-03-077644","article-title":"One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation","volume":"110","author":"Erard","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2021031815154413700_B8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1399-0012.2008.00877.x","article-title":"Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for varicella-zoster virus infection after allogeneic peripheral blood stem cell transplantation","volume":"22","author":"Kim","year":"2008","journal-title":"Clin Transplant"},{"issue":"6","key":"2021031815154413700_B9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21152","article-title":"Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation","volume":"83","author":"Asano-Mori","year":"2008","journal-title":"Am J Hematol"},{"issue":"11","key":"2021031815154413700_B10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bmt.1704959","article-title":"The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation","volume":"35","author":"Thomson","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2021031815154413700_B11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bmt.1703214","article-title":"Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Kanda","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2021031815154413700_B12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbmt.2018.04.003","article-title":"Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients?","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021031815154413700_B13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.bbmt.2019.04.015","article-title":"Severe herpes zoster requiring intravenous antiviral treatment in allogeneic hematopoietic cell transplantation recipients on standard acyclovir prophylaxis","volume":"25","author":"Baumrin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2021031815154413700_B14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2021031815154413700_B15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2021031815154413700_B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2013.11.013","article-title":"Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients","volume":"20","author":"Issa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021031815154413700_B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.22196","article-title":"Experience with use of Zostavax(\u00ae) in patients with hematologic malignancy and hematopoietic cell transplant recipients","volume":"87","author":"Naidus","year":"2012","journal-title":"Am J Hematol"},{"issue":"22","key":"2021031815154413700_B18","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2021031815154413700_B19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2021031815154413700_B20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"issue":"2","key":"2021031815154413700_B21","first-page":"181","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2021031815154413700_B22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2021031815154413700_B23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial [published correction appears in Cancer. 2020;126(12):2941]","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"2021031815154413700_B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"2021031815154413700_B25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2021031815154413700_B26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciu970","article-title":"Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation","volume":"60","author":"Bhalla","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"19","key":"2021031815154413700_B27","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2020002269","article-title":"Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study","volume":"4","author":"Camargo","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2021031815154413700_B28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/bloodadvances.2016000836","article-title":"Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir\/valacyclovir followed by vaccination","volume":"1","author":"Jamani","year":"2016","journal-title":"Blood Adv"},{"key":"2021031815154413700_B29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.antiviral.2017.01.011","article-title":"Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"140","author":"Seo","year":"2017","journal-title":"Antiviral Res"},{"issue":"8","key":"2021031815154413700_B30","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41409-019-0717-8","article-title":"Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation","volume":"55","author":"Mascarenhas","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2021031815154413700_B31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bmt.2015.239","article-title":"Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma","volume":"51","author":"Locke","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1585\/1803384\/advancesadv2020003749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1585\/1803384\/advancesadv2020003749.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:16:16Z","timestamp":1616066176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1585\/475466\/Safety-and-reactogenicity-of-the-recombinant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003749","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}